AstraZeneca (LSE: AZN) today announced that the European Commission has approved its Qtern (saxagliptin/dapagliflozin) tablets for the treatment of type 2 diabetes in all 28 European Union member countries plus Iceland, Liechtenstein and Norway.
The approval follows a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) at its May 2016 meeting. The fixed-dose combination of saxagliptin and dapagliflozin is the first DPP-4i/SGLT-2i combination product to be approved in Europe.
Last October, the Anglo-Swedish pharma major failed to win US approval for a new diabetes treatment that combines two of its existing drugs after the Food and Drug Administration issued a complete response letter calling for additional data that may require new clinical trials.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze